Skip to main content


Global Public Health

Global Public Health  

Throughout our more than 130-year history, Johnson & Johnson has ad a legacy of coming to the aid of local and global communities during times of crisis, from natural disasters to health outbreaks.  We believe we have a responsibility to step in and invest in  solutions for global public health crises and we are immensely proud to be making such significant contributions.                   

COVID-19 has had an unprecedented impact on the world as we know it.  The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to rapid scientific progress toward treatment and prevention measures for this global health crisis.

As a part of our ongoing efforts to help stem the COVID-19 pandemic, our goal is to provide a global supply of more than one billion vaccine doses through the course of 2021, if proven to be effective with a good safety profile.  For more information on our road to a vaccine, click here.

Since January 2020, Johnson & Johnson has been working directly with Governments and health authorities to help end this fast-moving pandemic, and we will continue to bring our full resources and best scientific minds to combat it - not just because we can, because we must.  For more information on our response to COVID-19, please click here.

Beyond COVID-19, as a leader in the field of global health, we remain focused on re-defining the treatment paradigm for infectious diseases affecting global communities, most notably including diseases like tuberculosis (TB) and Ebola.

We are also working with the not-for-profit Drugs for Neglected Diseases initiative (DNDi) on the pre-clinical programme for a potential new treatment against parasites that cause elephantiasis and river blindness — two of the most difficult-to-treat neglected tropical diseases (NTDs).

Janssen has also invested £10 million in a UK Government-led global Dementia Discovery Fund that will support innovative research to help find new ways to prevent and treat dementia and alzheimer’s disease. This brings together industry, Governments and non-profit organisations to create new sources of investment to support this research1.

International Health Partners (IHP)- Medicines for those in need

We are proud to partner with International Health Partners (IHP) to donate products to crisis-hit communities and help eradicate suffering caused by poor access to medicine. IHP help vulnerable people by overseeing, co-ordinating and delivering strategic medical product donations to those in desperate need of healthcare around the world.






1. Dementia Discovery Fund (2015) Launch of Dementia Discovery Fund